Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Eligible age
18–30 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
More than 40% of young adults with type 1 diabetes (T1D) also have overweight or obesity. Each of these diagnoses increase the risk of adverse cardiovascular events. GLP-1 analogues are anti-obesity medications that are cardioprotective in adults with type 2 diabetes, however evaluation of these agents in people with T1D has been limited to glycemic outcomes. Investigators aim to study the impact of GLP-1 analogue obesity treatment on markers of cardiometabolic risk in young adults with T1D and obesity.
Sponsor: Yale University
You may qualify if…
- ✓ Age 18-30 years with T1D whose BMI meets FDA approval criteria for anti-obesity pharmacotherapy (BMI ≥30 kg/m2 alone or BMI ≥27 kg/m2 with a weight-related comorbidity)
- ✓ Clinical diagnosis of T1D
- ✓ Diabetes duration diagnosed ≥ 12 months ago
- ✓ HbA1c ≤10% at screening and within the past 90 days
- ✓ Stable reported insulin dosing in the past 90 days (within 15%)
- ✓ Stable reported BMI in the past 90 days (within 5%)
- ✓ Ability to provide written informed consent before any trial-related activities
- ✓ Use of real-time continuous glucose monitoring and planned continued use
You may not qualify if…
- ✕ Use of adjunctive diabetes therapies or anti-obesity medications (including any GLP-1 agonist) currently or within the past 6 months.
- ✕ Insulin dosing \<0.5 units/kg/day
- ✕ Current psychiatric conditions impacting weight, including known eating disorders
- ✕ Contraindications to study medications, including:
- ✕ Personal history of pancreatitis, renal impairment, or known liver disease other than non-alcoholic hepatic steatosis
- ✕ Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia Type 2
- ✕ Known or suspected allergy to semaglutide, excipients, or related products.
- ✕ Use of lipid lowering medications other than statins and omega-3 products
Where it's recruiting
New Haven
Source: ClinicalTrials.gov · NCT06411210 · last updated 2026-08-04